BergenBio Fundamentale Forhold (BGBIO)

[BillyP]

Er vel forskjell på NOK og USD? Synes ikke dobling er enormt langt unna

[Sleeperts]

…ja…og 11.1 milliard dollar er 111 milliarder kroner som er sykt mye mindre en 220 milliarder kroner…eller syns du ikke det

Men du toucher problemet, folk tenker det er bare en dobling, men det er altså 110 milliarder unna. Det er en vanvittig forskjell

[vcp]

Korrekt, jeg overså tallene, de er ikke riktige. 3,29 billion usd, estimater for 2020

Men essensen er riktig og interessant.
Om jeg ikke misforstod dette punktet i Arctic sec presentasjonen så treffer Bgbio på 50% av keytruda markedet.

En lisensieringsavtale der, vel

[Sleeperts]

Absolutt ingen kritikk til deg/dere! Og hvis de når 3.29 økning i 2020 snakker vi en vanvittig block buster, hvis BGBIO øker dette med 1 % kan vi le hele veien til banken! Mest kritikk til enkelte på FA og enkelte på PCI som jeg mener har mistet kontakten med tall. 100 milliarder leste jeg at PCI skulle bli kjøpt for.

[vcp]

100 milliarder leste jeg at PCI skulle bli kjøpt for.

Håper de får rett, eller nesten, 50milliarder
Da er barna sikret for livet. De har pt. Sortert etter størrelse BGBIO/pcib /index.

[TekBot]

BerGenBio ASA: Resolution to carry out a share capital increase in connection with the Subsequent Offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE
SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG
SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR
…

Vis børsmeldingen

JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT
THE END OF THE PRESS RELEASE

Bergen, Norway, 19 June 2020: Reference is made to the stock exchange
announcement dated 4 May 2020 by BerGenBio ASA (the “Company”) regarding the
successful placed Private Placement raising gross proceeds of NOK 500 million
(the “Private Placement”) and the stock exchange announcement on 5 May 2020
relating to the subsequent offering and listing of up to 1,500,000 new shares,
each with a nominal value of NOK 0.10 (the “Offer Shares”) at a subscription
price of NOK 37.50 per Offer Share (the “Subscription Price”) to be carried out
by the Company (the “Subsequent Offering”).

Reference is also made to the announcement made on 29 May 2020, where BerGenBio
ASA announced a Notice of a Extraordinary General Meeting to be held on 19 June
2020 at 15:00 hours CET at the company’s offices in Møllendalsbakken 9, 5009
Bergen.

The Extraordinary General Meeting has been held and all proposals were resolved
as presented in the notice convening the Extraordinary General Meeting
distributed on 29 May 2020, as further set out in the minutes from the annual
general meeting attached hereto and available at
https://www.bergenbio.com/investors/general-meetings/

During the Extraordinary General Meeting, the decision was made to increase the
share capital by up to NOK 150,000 by issuing up to 1,500,000 offer shares in
the Subsequent Offering. The subscription period in the Subsequent Offering will
commence at 09:00 (CET) on 22 June 2020 and end at 16:30 (CET) on 3 July 2020.

Shareholders in the Company as of 4 May 2020, as registered as shareholders in
the Company’s register of shareholders in the Norwegian Central Security
Depository (VPS) as of 6 May 2020 (“Record date”) and who were not allocated
shares in the Private Placement, are not resident in a jurisdiction where such
offering would be unlawful or, for jurisdictions other than Norway, would
require any prospectus, filing, registration or similar action, and had an
existing shareholding below a threshold of 150 000 shares in the Company at the
Record date will be granted non-transferable subscription rights that, subject
to applicable law, provide preferential rights to subscribe for, and be
allocated, shares in the Subsequent Offering. Shareholder will receive 0.09352
subscription rights for each share registered as held on the Record Date.

The new shares in the Subsequent Offering will be allocated on or about 3 July
2020, and are expected to be delivered on or about 14 July 2020. Further
information on the Subsequent Offering is included in the Prospectus.

Arctic Securities AS, Carnegie AS and DNB Markets, a part of DNB Bank ASA
(together the “Managers”) are acting as Joint Bookrunners and Managers for the
Subsequent Offering.

Advokatfirmaet Thommessen AS is acting as the Company’s legal adviser for the
Subsequent Offering.

• END -

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

• IMPORTANT INFORMATION -

This document is not an offer to sell or a solicitation of offers to purchase or
subscribe for shares. Copies of this document may not be sent to jurisdictions,
or distributed in or sent from jurisdictions, in which this is barred or
prohibited by law. The information contained herein shall not constitute an
offer to sell or the solicitation of an offer to buy, in any jurisdiction in
which such offer or solicitation would be unlawful prior to registration,
exemption from registration or qualification under the securities laws of any
jurisdiction.

This communication may not be published, distributed or transmitted in or into
the United States, Canada, Australia, the Hong Kong Special Administrative
Region of the People’s Republic of China, South Africa or Japan and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States of America or to U.S. persons (as defined in the U.S.
Securities Act of 1933, as amended (the “Securities Act”)) or to publications
with a general circulation in the United States of America. This document is not
an offer for sale of securities in the United States. The securities referred to
herein have not been and will not be registered under the Securities Act, or the
laws of any state, and may not be offered or sold in the United States of
America absent registration under or an exemption from registration under
Securities Act. BerGenBio does not intend to register any part of the offering
in the United States. There will be no public offering of the securities in the
United States of America.

The information contained herein does not constitute an offer of securities to
the public in the United Kingdom. No prospectus offering securities to the
public will be published in the United Kingdom. This document is only being
distributed to and is only directed at (i) persons who are outside the United
Kingdom or (ii) to investment professionals falling within article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
“Order”) or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within article 49(2)(a) to (d) of the Order
(all such persons together being referred to as “relevant persons”). The
securities are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in only
with, relevant persons. Any person who is not a relevant person should not act
or rely on this document or any of its contents.

Any offer of securities to the public that may be deemed to be made pursuant to
this communication in any member state of the European Economic Area (each an
“EEA Member State”) that has implemented Directive 2003/71/EC (together with the
2010 PD Amending Directive 2010/73/EU, including any applicable implementing
measures in any Member State, the “Prospectus Directive”) is only addressed to
qualified investors in that Member State within the meaning of the Prospectus
Directive. This announcement is not a prospectus within the meaning of the
Prospectus Directive, as implemented in each member State of the European
Economic Area. With respect to the EEA Member States, no action has been
undertaken or will be undertaken to make an offer to the public of the
securities referred to herein requiring a publication of a prospectus in any
Member State. As a result, the securities of the Company may not and will not be
offered in any Member State except in accordance with the exemptions set forth
in Article 3 of the Prospectus Directive.

Investing in securities involves certain risks.

This publication may contain specific forward-looking statements, e.g.
statements including terms like “believe”, “assume”, “expect”, “forecast”,
“project”, “may”, “could”, “might”, “will” or similar expressions. Such forward
-looking statements are subject to known and unknown risks, uncertainties and
other factors which may result in a substantial divergence between the actual
results, financial situation, development or performance of BerGenBio and those
explicitly or implicitly presumed in these statements. Against the background of
these uncertainties, readers should not rely on forward-looking statements.
BerGenBio assumes no responsibility to update forward -looking statements or to
adapt them to future events or developments.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

BerGenBio ASA: Approval of Prospectus

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE
SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG
SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR
…

Vis børsmeldingen

JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT
THE END OF THE PRESS RELEASE

Bergen, Norway, 19 June 2020: Reference is made to the stock exchange
announcements dated 4 May 2020 by BerGenBio ASA (the “Company”) regarding the
successful private placement raising gross proceeds of NOK 500 million (the
“Private Placement”) through the allocation of 13,325,000 new shares in the
Company and a subsequent offering and listing of up to 1,500,000 new shares in
the Company, each with a nominal value of NOK 0.10 (the “Offer Shares”) at a
subscription price of NOK 37.50 per Offer Share (the “Subscription Price”) to be
carried out by the Company (the “Subsequent Offering”).

Further reference is made to the General Meeting held on 19 June 2020, at which
the decision was made to increase the share capital by up to NOK 150,000 by
issuing up to 1,500,000 Offer Shares.

Today, the Financial Supervisory Authority of Norway has also approved the
prospectus dated 19 June 2020 (the “Prospectus”) which has been prepared in
connection with the Subsequent Offering. The Prospectus will, subject to
regulatory restrictions in certain jurisdictions, be made available on the
following website: www.bergenbio.com/investors/reports/ Printed copies of the
prospectus may also be obtained free of charge at the offices of BerGenBio,
Jonas Lies vei 91, 5009 Bergen, or by contacting the Managers (as defined
below).

The subscription period for the Subsequent Offering will start at 09:00 CET on
22 June 2020 and will end at 16:30 hours (CET) on 3 July 2020 (the “Subscription
Period”). The payment for Offer Shares allocated to a subscriber falls due on 8
July 2020. The share capital increase pertaining to the Subsequent Offering is
expected to be registered with the Norwegian Register of Business Enterprises
(Nw.: Foretaksregisteret) on or about 13 July 2020. The Offer Shares are
expected to be delivered to the subscribers and commence trading on the Oslo
Stock Exchange on or about 14 July 2020.

Arctic Securities AS, Carnegie AS and DNB Markets, a part of DNB Bank ASA
(together the “Managers”) are acting as Joint Bookrunners and Managers for the
Subsequent Offering.

Advokatfirmaet Thommessen AS is acting as the Company’s legal adviser for the
Private Placement and the Subsequent Offering.

• END -

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

• IMPORTANT INFORMATION -

This document is not an offer to sell or a solicitation of offers to purchase or
subscribe for shares. Copies of this document may not be sent to jurisdictions,
or distributed in or sent from jurisdictions, in which this is barred or
prohibited by law. The information contained herein shall not constitute an
offer to sell or the solicitation of an offer to buy, in any jurisdiction in
which such offer or solicitation would be unlawful prior to registration,
exemption from registration or qualification under the securities laws of any
jurisdiction.

This communication may not be published, distributed or transmitted in or into
the United States, Canada, Australia, the Hong Kong Special Administrative
Region of the People’s Republic of China, South Africa or Japan and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States of America or to U.S. persons (as defined in the U.S.
Securities Act of 1933, as amended (the “Securities Act”)) or to publications
with a general circulation in the United States of America. This document is not
an offer for sale of securities in the United States. The securities referred to
herein have not been and will not be registered under the Securities Act, or the
laws of any state, and may not be offered or sold in the United States of
America absent registration under or an exemption from registration under
Securities Act. BerGenBio does not intend to register any part of the offering
in the United States. There will be no public offering of the securities in the
United States of America.

The information contained herein does not constitute an offer of securities to
the public in the United Kingdom. No prospectus offering securities to the
public will be published in the United Kingdom. This document is only being
distributed to and is only directed at (i) persons who are outside the United
Kingdom or (ii) to investment professionals falling within article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
“Order”) or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within article 49(2)(a) to (d) of the Order
(all such persons together being referred to as “relevant persons”). The
securities are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in only
with, relevant persons. Any person who is not a relevant person should not act
or rely on this document or any of its contents.

Any offer of securities to the public that may be deemed to be made pursuant to
this communication in any member state of the European Economic Area (each an
“EEA Member State”) that has implemented Directive 2003/71/EC (together with the
2010 PD Amending Directive 2010/73/EU, including any applicable implementing
measures in any Member State, the “Prospectus Directive”) is only addressed to
qualified investors in that Member State within the meaning of the Prospectus
Directive. This announcement is not a prospectus within the meaning of the
Prospectus Directive, as implemented in each member State of the European
Economic Area. With respect to the EEA Member States, no action has been
undertaken or will be undertaken to make an offer to the public of the
securities referred to herein requiring a publication of a prospectus in any
Member State. As a result, the securities of the Company may not and will not be
offered in any Member State except in accordance with the exemptions set forth
in Article 3 of the Prospectus Directive.

Investing in securities involves certain risks.

This publication may contain specific forward-looking statements, e.g.
statements including terms like “believe”, “assume”, “expect”, “forecast”,
“project”, “may”, “could”, “might”, “will” or similar expressions. Such forward
-looking statements are subject to known and unknown risks, uncertainties and
other factors which may result in a substantial divergence between the actual
results, financial situation, development or performance of BerGenBio and those
explicitly or implicitly presumed in these statements. Against the background of
these uncertainties, readers should not rely on forward-looking statements.
BerGenBio assumes no responsibility to update forward -looking statements or to
adapt them to future events or developments.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Savepig]

Herlig! Jeg kommer til å tegne

[TekBot]

BerGenBio ASA: Commencement of the subsequent offering

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, TO U.S. NEWS WIRE
SERVICES, OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG
SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA OR
…

Vis børsmeldingen

JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE
UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT
THE END OF THE PRESS RELEASE

Bergen, Norway, 19 June 2020: Reference is made to the stock exchange
announcement dated 4 May by BerGenBio ASA (the “Company”) relating to the
Subsequent Offering and listing of up to 1,500,000 new shares in the Company,
each with a nominal value of NOK 0.10 (the Offer Shares") at a subscription
price of NOK 37.50 per Offer Share (the Subscription Price") to be carried out
by the Company (the “Subsequent Offering”) and the stock exchange announcement
from the Company on 19 June 2020 regarding the extraordinary General Meeting’s
resolution to increase the share capital in connection with the Subsequent
Offering.

The subscription period for the Subsequent Offering commences at 09:00 hours
(CET) on 22 June 2020 and expires at 16:30 hours (CET) on 3 July 2020 (the
“Subscription Period”).

Shareholders in the Company as of 4 May 2020 that have been registered as such
in the Norwegian Central Security Depository (VPS) as of 6 May 2020 (the “Record
Date”), and who were not allocated shares in the private placement announced by
the Company on 4 May 2020 and who are not resident in a jurisdiction where such
offering would be unlawful, or for jurisdictions other than Norway, would
require any filing, registration or similar action, and have an existing
shareholding below a threshold of 150,000 shares in the Company (the “Eligible
Shareholders”), will be granted non-transferable subscription rights (the
“Subscription Rights”) that, subject to applicable law, provide preferential
rights to subscribe for, and be allocated, Offer Shares at the Subscription
Price.

Each Eligible Shareholder will, subject to applicable securities laws, be
granted 0.09352 Subscription Rights for every existing share registered as held
by such Eligible Shareholder as of the Record Date, rounded down to the nearest
whole Subscription Right. Each Subscription Right will, subject to applicable
securities laws, give the right to subscribe for, and be allocated, one Offer
Share in the Subsequent Offering. Over-subscription is permitted, however,
subscription without Subscription Rights is not permitted.

Please note that Subscription Rights that are not used to subscribe for Offer
Shares before the end of the Subscription Period will have no value and will
lapse without compensation to the holder.

A prospectus dated 19 June 2020 (the “Prospectus”) prepared in connection with
the Subsequent Offering is, subject to regulatory restrictions in certain
jurisdictions, available at https://www.bergenbio.com/investors/reports/. Hard
copies of the Prospectus may be obtained free of charge at the offices of the
Company at Jonas Lies vei 91, 5009 Bergen, Norway, or by contacting the Managers
(defined below).

Following the completion of the Subsequent Offering, and assuming full
subscription, the number of shares outstanding in the Company will increase by
1,500,000 shares to 88,225,805 shares, each with a nominal value of NOK 0.10,
resulting in a total share capital of NOK 8,822,580.50.

The timetable below provides certain key dates for the Subsequent Offering:

Subscription Period commences: 22 June 2020 at 09:00 (CET)

Subscription Period ends: 3 July 2020 at 16:30 hours (CET)

Allocation of the Offer Shares and distribution of allocation letters: Expected
on or about 3 July 2020

Payment date: 8 July 2020

Delivery of the Offer Shares and listing and commencement of trading in the
Offer Shares on Oslo Børs: Expected on or about 14 July 2020. For further
details on the terms of the Subsequent Offering, please see the Prospectus.

Arctic Securities AS, Carnegie AS and DNB Markets, a part of DNB Bank ASA
(together the “Managers”) are acting as Joint Bookrunners and Managers for the
Subsequent Offering.

Advokatfirmaet Thommessen AS is acting as the Company’s legal adviser for the
Subsequent Offering.

• END -

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company’s proprietary lead candidate, bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad phase II oncology clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID19. A first-in-class functional blocking anti-AXL antibody,
tilvestamab, is undergoing phase I clinical testing. In parallel, BerGenBio is
developing companion diagnostic tests to identify patient populations most
likely to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com

Contacts

Richard Godfrey CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86 513

• IMPORTANT INFORMATION -

This document is not an offer to sell or a solicitation of offers to purchase or
subscribe for shares. Copies of this document may not be sent to jurisdictions,
or distributed in or sent from jurisdictions, in which this is barred or
prohibited by law. The information contained herein shall not constitute an
offer to sell or the solicitation of an offer to buy, in any jurisdiction in
which such offer or solicitation would be unlawful prior to registration,
exemption from registration or qualification under the securities laws of any
jurisdiction.

This communication may not be published, distributed or transmitted in or into
the United States, Canada, Australia, the Hong Kong Special Administrative
Region of the People’s Republic of China, South Africa or Japan and it does not
constitute an offer or invitation to subscribe for or purchase any securities in
such countries or in any other jurisdiction. In particular, the document and the
information contained herein should not be distributed or otherwise transmitted
into the United States of America or to U.S. persons (as defined in the U.S.
Securities Act of 1933, as amended (the “Securities Act”)) or to publications
with a general circulation in the United States of America. This document is not
an offer for sale of securities in the United States. The securities referred to
herein have not been and will not be registered under the Securities Act, or the
laws of any state, and may not be offered or sold in the United States of
America absent registration under or an exemption from registration under
Securities Act. BerGenBio does not intend to register any part of the offering
in the United States. There will be no public offering of the securities in the
United States of America.

The information contained herein does not constitute an offer of securities to
the public in the United Kingdom. No prospectus offering securities to the
public will be published in the United Kingdom. This document is only being
distributed to and is only directed at (i) persons who are outside the United
Kingdom or (ii) to investment professionals falling within article 19(5) of the
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the
“Order”) or (iii) high net worth entities, and other persons to whom it may
lawfully be communicated, falling within article 49(2)(a) to (d) of the Order
(all such persons together being referred to as “relevant persons”). The
securities are only available to, and any invitation, offer or agreement to
subscribe, purchase or otherwise acquire such securities will be engaged in only
with, relevant persons. Any person who is not a relevant person should not act
or rely on this document or any of its contents.

Any offer of securities to the public that may be deemed to be made pursuant to
this communication in any member state of the European Economic Area (each an
“EEA Member State”) that has implemented Directive 2003/71/EC (together with the
2010 PD Amending Directive 2010/73/EU, including any applicable implementing
measures in any Member State, the “Prospectus Directive”) is only addressed to
qualified investors in that Member State within the meaning of the Prospectus
Directive. This announcement is not a prospectus within the meaning of the
Prospectus Directive, as implemented in each member State of the European
Economic Area. With respect to the EEA Member States, no action has been
undertaken or will be undertaken to make an offer to the public of the
securities referred to herein requiring a publication of a prospectus in any
Member State. As a result, the securities of the Company may not and will not be
offered in any Member State except in accordance with the exemptions set forth
in Article 3 of the Prospectus Directive.

Investing in securities involves certain risks.

This publication may contain specific forward-looking statements, e.g.
statements including terms like “believe”, “assume”, “expect”, “forecast”,
“project”, “may”, “could”, “might”, “will” or similar expressions. Such forward
-looking statements are subject to known and unknown risks, uncertainties and
other factors which may result in a substantial divergence between the actual
results, financial situation, development or performance of BerGenBio and those
explicitly or implicitly presumed in these statements. Against the background of
these uncertainties, readers should not rely on forward-looking statements.
BerGenBio assumes no responsibility to update forward -looking statements or to
adapt them to future events or developments.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[Magnus1]

Selvsagt👌

[Hpbjorn]

Fantastisk! Gode nyheter på en ellers strålende fredag! Ikke bare tegning men overtegning!

[Investor]

Herlig! Jeg kommer til å tegne

Du hadde jo ikke aksjer, Savepig?

Eller husker jeg feil?

[ezPappi]

Jeg også. Var slettes ikke dumt å gjøre det sist

[Savepig]

Man må jo ha noen aksjer i biotechen over tunet.

[lasseht]

når og hvor kan man kjøpe R emi aksjer

[Hpbjorn]

Du må ha eid aksjer den 4.mai ved børsslutt (registrert i vps 6.mai). Da kan du tegne (22.juni-3.juli). Logg inn på vps.no med bankid så skal det være mulig å gjøre det der. Betaling skjer 8.juli og vil tro instrukser for dette kommer etterhvert. Ellers er tipset å lese børsmeldinger og info fra selskapet. Lykke til.

[Urquell]

Mener det skal holde at aksjene er kjøpt innen børsen stenger 6. mai. At det er en lagg før de registreres i VPS bør ikke bety noe i denne sammenheng. All relevant info finnes uansett elektronisk, deriblant tidspunkt for kjøp. Noen som kan bekrefte (eller avkrefte) dette?

[BillyP]

Står jo tydelig 4. mai. Og Oslo børs opererer med T+2 for registrering av verdipapirer etter en transaksjon. Endringer 4. mai ble registrert 6. mai i VPS.

Shareholders in the Company as of 4 May 2020 that have been registered as such
in the Norwegian Central Security Depository (VPS) as of 6 May 2020 (the “Record
Date”).

[Urquell]

Takker! Så flere refererte til 6 mai, så antok det var den kritiske dato for kjøp. Men ser nå at det, for min del, dessverre ikke stemmer. Da blir det litt færre emisjonsaksjer.

[arcone]

For dere som har vært med på ett par emisjoner før. Ved en slik emi vi ser nå, bør vi forberede oss på at kursen dropper ned til NOK 37.50 før vi går videre opp?